Exicure, Inc. (NASDAQ:XCUR – Get Free Report) was the target of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 18,000 shares, a decrease of 67.8% from the September 30th total of 55,900 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.7% of the shares of the stock are short sold.
Exicure Stock Performance
Shares of NASDAQ XCUR traded up $0.05 during trading on Friday, hitting $2.38. The company had a trading volume of 381 shares, compared to its average volume of 487,682. The business’s 50-day moving average is $2.15 and its 200 day moving average is $1.04. The company has a market cap of $4.12 million, a P/E ratio of -0.52 and a beta of 1.28. Exicure has a 52 week low of $1.44 and a 52 week high of $6.00.
Exicure (NASDAQ:XCUR – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter.
Insider Buying and Selling
Exicure Company Profile
Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
See Also
- Five stocks we like better than Exicure
- Airline Stocks – Top Airline Stocks to Buy Now
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- EV Stocks and How to Profit from Them
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.